Durvalumab May Improve Survival of Non-small Cell Lung Cancer Patients

by Iswarya on  September 28, 2018 at 5:26 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Patients with non-small cell lung cancer survive longer when their therapy includes durvalumab following platinum-based chemoradiotherapy, reports a new study. The findings of the study are published in the New England Journal of Medicine.
Durvalumab May Improve Survival of Non-small Cell Lung Cancer Patients
Durvalumab May Improve Survival of Non-small Cell Lung Cancer Patients

Durvalumab (Imfinzi®) is an immune checkpoint inhibitor that received United States Food and Drug Administration (FDA) approval in February as a new standard-of-care option for patients with stage 3 non-small cell lung cancer where surgery is not an option and whose disease has not progressed following platinum-based chemoradiotherapy.

The therapy, administered intravenously, helps increase T cell activation by blocking a protein called PD-L1 (programmed cell death ligand 1).

Manufactured by AstraZeneca, durvalumab received initial FDA approval in 2017 for locally advanced or metastatic bladder cancer. But Scott Antonia, M.D., Ph.D., chair of the Department of Thoracic Oncology at Moffitt, saw the potential of durvalumab as a treatment option for patients with advanced non-small cell lung cancer.

Working with AstraZeneca, he launched the PACIFIC clinical trial, a randomized, double-blind, placebo-controlled international phase 3 trial that spanned 235 investigative sites in 26 countries and enrolled more than 700 patients.

"Approximately one-third of patients with non-small cell lung cancer have advanced stage 3 disease at the time of diagnosis. Standard treatment has been chemotherapy and radiation, but 85 percent of patients do not respond to the therapy," said Antonia. "Adding durvalumab to the standard treatment has made a big impact for this group of patients. It's allowing them to live longer and potentially increasing their chance for cure."

The new clinical trial data are based on a two-year follow-up of patients participating in the trial. The findings include:
  • Progression-free survival was 17.2 months with durvalumab compared to 5.6 months with placebo
  • Overall survival rate at two years was 66.3 percent with durvalumab compared to 55.6 percent with placebo
  • Of the patients who had a response to durvalumab, 73.5 percent had an ongoing response at 18 months compared with 52.2 percent in the placebo group


Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

More News on:

Lung Biopsy Lung Cancer Cancer and Homeopathy Parkinsons Disease Surgical Treatment Cancer Facts Asbestosis Cancer Tattoos A Body Art Pneumoconiosis Smoking among Women 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive